Has Timothy Korytko, MD received payments from drug or device companies?

Yes. Drug and device makers reported $91,318 in general payments to Timothy Korytko, MD across 98 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Timothy Korytko, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Timothy Korytko, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Timothy Korytko, MD

Radiation Oncology · Cooperstown, NYNPI 1205050739

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 85.1% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $25,956, 5.2 times the $4,990 reported in 2019. Among radiation oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$91,318in general payments, 2019–2025

Across 98 payments — averaging $931.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$78K
Sanofi$5K
Bayer$3K
Pfizer$2K
Telix Pharmaceuticals$2K
Tersera Therapeutics LLC$356
plus $1K from 14 others

$5,355in research payments, 2019–2025

Across 2 payments — averaging $2677.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$5K

What the payments were for

Consulting fees$24,63327%
Speaking & faculty fees$54,45060%
Travel & lodging$8,78710%
Food & beverage$3,4484%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	46	$77,721
Sanofi	8	$5,091
Bayer	2	$3,477
Pfizer	3	$1,733
Telix Pharmaceuticals	6	$1,562
Tersera Therapeutics LLC	1	$356
Novartis	11	$356
Novocure Inc.	4	$307
E.r. Squibb & Sons, L.L.C.	4	$146
Sirtex Medical Inc	2	$141
Ipsen Biopharmaceuticals, Inc	1	$125
Siemens Medical Solutions USA, Inc.	1	$66
Foundation Medicine, Inc.	1	$61
Boston Scientific	2	$41
Iovance Biotherapeutics, Inc.	1	$24
Daiichi Sankyo Inc.	1	$23
Myovant Sciences GmbH	1	$23
Beigene USA, Inc.	1	$22
Takeda Pharmaceuticals U.S.A., Inc.	1	$22
Myriad Genetic Laboratories, Inc.	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,318 in reported general payments places this provider in the 95th percentile of 397 radiation oncology providers in New York.

See all radiation oncology providers in New York →

Medicare billing

Part B allowed, 2024

$185,454

Medicare patients

285

Services billed

2,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OrgovyxRelugolix	31	$82,527
Tamsulosin Hcl	131	$1,403
Memantine Hcl	21	$334
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	13	$135
Finasteride	15	$126
Pantoprazole Sodium	11	$118
Methylprednisolone	11	$72
Venlafaxine Hcl ErVenlafaxine Hcl	25	$59
Gabapentin	11	$55

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Cooperstown

Chung ChungSyracuse$3.1M
Michael ZelefskyNew York$946K
Jeffrey BogartSyracuse$772K
Steven FinkelsteinSyracuse$578K
Shawn ZimbergPlainview$411K
Edward ObedianOyster Bay$391K
Nancy LeeNew York$233K
Dheerendra PrasadBuffalo$178K
Robert SamsteinNew York$125K
Jalal AhmedNew York$100K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →